DOI: http://dx.doi.org/10.18203/2349-3291.ijcp20151482

Prevalence and predictors for lipodystrophy syndrome among HIV infected children on anti-retroviral therapy

Sanjeeva G. N., Pavithra H. B., Sukanya V., Shobha S., Govindaraj M.

Abstract


Background: With the widespread use of ART and prolonged survival of CLHIV, toxicities like lipodystrophy are increasingly evident. There are limited pediatric data on the prevalence of Lipodystrophy syndrome (LDS). The aim of this study was to determine the prevalence and predictors associated with LDS among HIV-infected children on ART.

Methods: A cross-sectional study of 320 CLHIV aged between 2-18 years on ART were enrolled. Fat redistribution (FR) was assessed clinically and fasting blood sample was taken for lipid profile. LDS was defined as FR or metabolic abnormalities or both. We conducted univariate, multivariate and adjusted analysis to determine factors predisposing to LDS.

Results: Median age of the participants was 13 years. Mean duration on ART was 3.7±1.9 years. Prevalence of LDS, FR, and metabolic abnormalities was 60%, 46% and 36% respectively. We found significant association between FR and age less than 5 yrs at the time of ART initiation, d4T exposure and duration of ART exposure of > 3yrs. Children who were moderately malnourished before ART initiation were less likely to develop FR and LDS (p=0.03). A significant association was also seen between metabolic abnormalities and female gender, advanced sexual maturity and hypertriglyceridemia at the time of ART initiation.

Conclusions: Prevalence of LDS is high among HIV-infected children on ART and likelihood of developing FR increases with prolonged exposure of ART as well as early age of initiation of ART. Advanced sexual maturation and hypertriglyceridemia at the time of ART initiation were associated with increased prevalence of metabolic abnormalities.


Keywords


Lipodystrophy, Prevalence, CLHIV, Antiretroviral therapy

Full Text:

PDF

References


Grunfeld C, Kotler D, Hamadeh R. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med. 1989;86:27–31.

Babl FE, Regan AM, Pelton SI. Abnormal body-fat distribution in HIV-1-infected children on antiretrovirals. Lancet. 1999;353(9160):1243-4.

Bockhorst JL, Ksseiry I, Toye M, Chipkin SR, Stechenberg BW. Evidence of human immunodeficiency virus-associated lipodystrophy syndrome in children treated with protease inhibitors. Pediatr Infect Dis J. 2003;22:463–65.

Jaquet D, Levine M, Ortega-Rodriguez E, Faye A, Polak M. Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS. 2000;14:2123–8.

National AIDS Control Organisation. Technical report India HIV Estimates. 2012. Available:http://www.naco.gov.in/upload/Surveillance/Reports%20&%20Publication/Technical%20Report%20-%20India%20HIV%20Estimates%202012.pdf. Accessed 10 December 2014.

National AIDS Control Organisation. Guidelines for HIV care and treatment in infants and children. 2006. Available:http://www.naco.gov.in/upload/Publication/Treatment%20Care%20and%20support/Guidelines%20for%20HIV%20care%20and%20treatment%20in%20Infants%20and%20children.pdf. Accessed 20 December 2014.

National AIDS Control Organisation. Pediatric antiretroviral therapy (ART) guidelines. 2013. Available: http://www.naco.gov.in/upload/2014%20mslns/CST/Pediatric_14-03-2014.pdf. Accessed 10 December 2014.

Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353(9170):2093-9.

Yip PM, Chan MK, Nelken J, Lepage N, Brotea G. Pediatric reference intervals for lipids and apolipoproteins on the VITROS 5,1 FS Chemistry System. Clin Biochem. 2006;39:978–83.

World Health Organization. United Nations Children's Fund WHO child growth standards and the identification of severe acute malnutrition in infants and children A joint statement. 2009. Available: http://www.who.int/nutrition/publications/severemalnutrition/9789241598163/en/. Accessed 20 December 2014.

World Health Organization. Growth reference 5-19 years. 2007. Available: www.who.int/growthref/who2007_bmi_for_age/en/. Accessed 10 December 2014.

Alam N, Cortina-Borja M, Goetghebuer T, Marczynska M, Vigano A. Body fat abnormality in HIV-infected children and adolescents living in Europe: prevalence and risk factors. J Acquir Immune Defic Syndr. 2012;59:314–24.

European Paediatric Lipodystrophy Group. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. Aids. 2004;18:1443–51.

Piloya T, Bakeera-kitaka S, Kekitiinwa A, Kamya MR. Lipodystrophy among HIV-infected children and adolescents on highly active antiretroviral therapy in Uganda : a cross sectional study. J Int AIDS Soc. 2012;15:1–7.

Children H, Beregszaszi M, Dollfus C, Levine M, Faye A. Longitudinal Evaluation and Risk Factors of Lipodystrophy and Associated Metabolic Changes in. J Acquir immune Defic Syndr. 2005;40:161–8.

Kinabo GD, Sprengers M, Msuya LJ, Shayo AM, van Asten H. Prevalence of lipodystrophy in HIV-infected children in Tanzania on highly active antiretroviral therapy. Pediatr Infect Dis J. 2013;32:39–44.

Ene L, Goetghebuer T, Hainaut M, Peltier A, Toppet V. Prevalence of lipodystrophy in HIV-infected children: a cross-sectional study. Eur J Pediatr. 2007;166:13–21.

World Health Organization Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection Recommendations for a public health approach. 2013. Available: http://www.who.int/hiv/pub/guidelines/arv2013/en/. Accessed 20 December 2014.

Amaya RA, Kozinetz CA, Mcmeans ANN, Schwarzwald H, Kline MW. Lipodystrophy syndrome in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2002;21:405-10.

European Paediatric Lipodystrophy Group. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. Aids. 2004;18:1443–51.

Torres AMS nchez, Muniz RM, Madero R, Borque C, Garcı´a-Miguel MJ s. Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children. Eur J Pediatr. 2005;164:271–6.

Hartman K, Verweel G, de Groot R, Hartwig NG. Detection of lipoatrophy in human immunodeficiency virus-1-infected children treated with highly active antiretroviral therapy. Pediatr Infect Dis J 2006;25:427–31.

Daniels SR, Greer FR. Lipid screening and cardiovascular health in childhood. Pediatrics. 2008;122:198–208.